4 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a five-year survival rate of 13%. Neoadjuvant therapy (NAT) is thought to reshape anti-tumor immunity, but its effects on circulating T cell composition/exhaustion and how this relates to intratum...
Importance Recent analyses raise concerns regarding the safety and cost of robotic cholecystectomy (RC) relative to laparoscopic cholecystectomy (LC); however, the analyses were limited by varied surgeon experience and inadequate adjustment for procedure difficulty. Objective To compare clinical outcomes and cost bet...
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of just 13%. Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet has shown limited efficacy in PDAC, benefiting fewer than 1% of patients to date. Contributing to this, the PDAC tumor microenvironment (TME) is desmoplastic and comp...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
